About Nuvaira
Nuvaira is a company based in Minneapolis (United States) founded in 2008. Nuvaira has raised $268.91 million across 11 funding rounds from investors including USVP, Endeavour Vision and Lightstone Ventures. The company has 57 employees as of December 31, 2022. Nuvaira offers products and services including dNerva Lung Denervation System. Nuvaira operates in a competitive market with competitors including RejuvenAir, Asthmatx and D R Burton, among others.
- Headquarter Minneapolis, United States
- Employees 57 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nuvaira, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$268.91 M (USD)
in 11 rounds
-
Latest Funding Round
$35.76 M (USD), Series E
Feb 20, 2026
-
Investors
USVP
& 12 more
-
Employee Count
57
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuvaira
Nuvaira offers a comprehensive portfolio of products and services, including dNerva Lung Denervation System.
Catheter-based system for one-time lung treatment to reduce COPD symptoms.
People of Nuvaira
Unlock access to complete
Unlock access to complete
Funding Insights of Nuvaira
Nuvaira has successfully raised a total of $268.91M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $35.76 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuvaira
Nuvaira has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include USVP, Endeavour Vision and Lightstone Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm that focuses on early stage investments in the US
|
Locked | Locked | Locked | |
|
Endeavour Vision is focused on transformative healthcare technology investments.
|
Locked | Locked | Locked | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Locked | Locked | Locked |
Investor details for Nuvaira
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuvaira
Investment portfolio details for Nuvaira
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nuvaira
Detailed financials for Nuvaira
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuvaira Comparisons
Peer comparison for Nuvaira
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuvaira
Nuvaira operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RejuvenAir, Asthmatx and D R Burton, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cryosurgical device for chronic bronchitis and COPD treatment is developed.
|
|
| Locked | Locked | Locked |
Bronchial thermoplasty devices are developed for adult asthma treatment.
|
|
| Locked | Locked | Locked |
Provides comprehensive products for positive pressure therapy in lung disease patients.
|
Detailed competitors of Nuvaira
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuvaira
Complete news archive for Nuvaira
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuvaira
Nuvaira was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Nuvaira is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Dennis Wahr is the current CEO of Nuvaira.
Nuvaira is a funded company, having raised a total of $268.91M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Nuvaira is 57.
Nuvaira was founded in 2008 in Minneapolis, United States, within the medical device sector focused on respiratory care. Operations center on the development of the Nuvaira Lung Denervation System, a catheter-based technology for chronic obstructive pulmonary disease (COPD). This system enables Targeted Lung Denervation (TLD), a procedure by which overactive airway nerves are ablated to relieve airway obstruction and support improved breathing function.
Nuvaira's top competitors include RejuvenAir, Asthmatx and D R Burton.
Nuvaira offers dNerva Lung Denervation System.
Nuvaira has 13 investors. Key investors include USVP, Endeavour Vision, Lightstone Ventures, Split Rock Partners, and Advanced Technology Ventures.